Sleep and Health Outcomes in Women With Heavy Menses

NCT ID: NCT05722444

Last Updated: 2024-03-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-06

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate subjective sleep over three consecutive menstrual cycles (menses and non-menses) in females reporting heavy menstrual bleeding. Following a baseline phase of one menstrual cycle, study subjects will use a standardized nighttime feminine product during menstruation for their second cycle. For the third cycle, subjects will continue to use the standardized menstrual product with behavioral modification that includes refraining from those sleep behaviors used to avoid nighttime menstrual leakage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menstruation; Heavy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Women with reported heavy menses

Group Type EXPERIMENTAL

Nighttime Feminine Product

Intervention Type OTHER

During nights while menstruating:

* Standardized nighttime feminine product + typical nighttime behaviors to prevent leak
* Standardized nighttime feminine product + refraining from nighttime behaviors to prevent leak

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nighttime Feminine Product

During nights while menstruating:

* Standardized nighttime feminine product + typical nighttime behaviors to prevent leak
* Standardized nighttime feminine product + refraining from nighttime behaviors to prevent leak

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged 18-50 years old
* Generally healthy (self-assessed; no significant underlying disease)
* Premenopausal patients with regular menstrual cycles every 21 to 35 days
* Patients with at least 3 days and no more than 7 days of bleeding during menstruation
* An intact uterus and at least one ovary
* Ability and willingness to provide written informed consent
* Willingness to adhere to study procedures
* Menstrual pads are the primary form for nighttime menstrual protection needs
* Will maintain a daily schedule that allows normal or typical sleep habits (ie, not a night-shift worker; \>5 hours of sleep).
* Women will self-report that they have heavy flow and perform at least one of the following compensatory behaviors:

* Set an alarm or plan to get up in the middle of the night to check or change the pad
* Add additional disposable absorbent products for extra leak protection of coverage (e.g. extra pads or liners)
* Use pillows or other means to limit sleep positions (to prevent moving at night)
* Use something extra on top of my bedding (such as a towel) to sleep on
* Wear an extra pair of pants/shorts
* Wear tighter clothing than they typically would, like yoga pants

Exclusion Criteria

* Currently pregnant or intending to imminently attempt pregnancy
* Any condition (social or medical) that, in the opinion of the primary care giver or study staff, would make trial participation unsafe or complicate data interpretation
* Difficult sleeping environment due to:

* Frequently involved in activities requiring nighttime awakenings (eg, taking care of an infant or loved one).
* Disruptive bed partners (i.e., snoring, children, pets, etc)
* Diagnosed sleep disorders (i.e. insomnia, sleep apnea, restless leg disorder, breathing disorder, etc)
* Use of an Intrauterine Device (IUDs) unless copper IUD.
* Regular use (\>1 day per week) of sleep aids and/or sedating medications, including over the counter products like melatonin.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Northwestern University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jessica Walter

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Dermatology, Northwestern University Feinberg School of Medicine

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STU00215465

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Social Media Usage in Adolescent Girls
NCT06426459 NOT_YET_RECRUITING
Melatonin Effects on Luteinizing Hormone
NCT00288262 TERMINATED PHASE1/PHASE2